- Reversal of moderate to deep neuromuscular blockade induced by rocuronium or vecuronium in patients undergoing surgery
- Emergency reversal (within 3 minutes) of rocuronium administration in difficult to intubate patients
The safety and efficacy in pediatric patients (less than 18 years of age) has not been established
- Available as 100 mg/mL injection solution. No reconstitution or further dilution necessary. May be diluted with 0.9% NS to 25 mg/mL for children less then 2 years
- Stable between 15 - 30 C
- Protect from light - use vial within 5 days when not protected from light
- Solutions Compatible: 0.9% NaCl, D5W, D5W/0.9%NaCl, Ringer's lactate, Ringer's solution
- Incompatible: ondansetron, ranitidine, verapamil
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
YES - rapid bolus within 10 seconds
Flush line with 0.9% NaCl between sugammadex & other drugs
|IV Intermittent Infusion||NO|
|IV Continuous Infusion||NO|
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- To reverse rocuronium or vecuronium induced NMB to recovery defined as a TOF (T1/T4 ratio of 0.9:
- Moderate blockade: 2 mg/kg/dose* IV
- Deep blockade: 4 mg/kg/dose* IV
* Based on actual body weight. Dosing and timing of sugammadex administration should be based on monitoring for twitch responses and the extent of spontaneous recovery that has occurred.
- Urgent Reversal of neuromuscular blockade following administration of a single dose of 1.2 mg/kg of rocuronium for intubation:
- 16 mg/kg/dose IV - NOT studied in the pediatric population for this indication.
- Hypersensitivity reactions: anaphylaxis or anaphylactoid reactions, may occur on first or subsequent exposure.
- Cardiovascular: marked bradycardia within minutes after administration. Bradycardia with cardiac arrest has occurred. For clinically significant bradycardia, treat with anti-cholinergic agents such as atropine.
- Haematologic: transient (<1 hour) increased in coagulation parameters (aPTT, PT, INR)
- Adverse Effects Greater than 10%: hypotension, headache, nausea and vomiting, pain at site of injection
- Adverse Effects 1– 10%: Prolonged QT interval on ECG, bradycardia, tachycardia
- Not recommended for patients with severe renal impairment and patients on dialysis